Sunday, November 22, 2026

Lord John and Lord Bernard Stuart, Anthony van Dyck (c.1638)

 


{Click on Image to Enlarge}

___

Public Domain.


Source: WikiArt, https://www.wikiart.org/en/anthony-van-dyck/lord-john-and-lord-bernard-stuart

____

Defining the #molecular #interaction between #influenza #hemagglutinin and #MHC-II

 


Abstract

The hemagglutinin (HA) of some influenza viruses can bind MHC-II, but how these proteins interact is unclear. Here we demonstrate that diverse H5 HAs can use avian or human MHC-II to enter cells. We define the molecular interface by using pseudovirus deep mutational scanning to measure how mutations to both H5 HA and an avian MHC-II affect the interaction between the two proteins. We leverage identification of mutations to HA and MHC-II that increase their binding to each other to determine a 3.4-angstrom cryo-EM structure of the complex. The structure shows that HA binds to MHC-II using a surface on the globular head distinct from the sialic acid receptor-binding pocket. The recognition surface on MHC-II consists of a portion of the alpha chain near the peptide-binding groove. We further show that H7 HA interacts with MHC-II similarly to H5 HA, and that H1, H2, and H9 HAs also bind avian or human MHC-II.


Competing Interest Statement

J.D.B. and B.D. are inventors on Fred Hutch licensed patents related to the pseudovirus deep mutational scanning and a provisional patent on MHC-II binding deficient HA vaccine antigens. J.D.B consults for Apriori Bio, GSK, Merck, and Pfizer. J.D.B. holds stock options in the Vaccine Company. N.P.K. is a paid consultant of AstraZeneca.


Funder Information Declared

National Institute of Allergy and Infectious Diseases, 75N93021C00015, U19AI181881

National Cancer Institute, P30CA015704

Washington Research Foundation, https://ror.org/00hasdx88, postdoctoral fellowship to Sara Sunshine

Howard Hughes Medical Institute, https://ror.org/006w34k90


Source: BioRxIV, https://doi.org/10.64898/2026.07.17.738765

____

Saturday, November 21, 2026

#Coronavirus Disease Research #References (AMEDEO, Nov. 21 '26)

 


    Antiviral Res

  1. TOLENTINO COLLADO J, Wang M, Li SX, Cifone MT, et al
    Time-Dependent Activity of SARS-CoV-2 M(pro) Inhibitors.
    Antiviral Res. 2026 Nov 20:106574. doi: 10.1016/j.antiviral.2026.106574.
    PubMed         Abstract available


    Emerg Infect Dis

  2. BOLEY PA, Hartley G, Saif LJ, Bowman AS, et al
    Zoonotic Exposure to Porcine Deltacoronavirus, United States, 2019-2021.
    Emerg Infect Dis. 2026;32:2107-2109.
    PubMed         Abstract available

  3. GOTERRIS L, Koster PC, Fuentes J, Sulleiro E, et al
    Post-COVID-19 Emergence and Spread of Hypertransmissible Cryptosporidium hominis gp60 Subtype IfA12G1R5, Spain.
    Emerg Infect Dis. 2026;32:2067-2071.
    PubMed         Abstract available


    Int J Infect Dis

  4. DING P, Yao Y, Li K, Huang Y, et al
    Viral detection and clinical heterogeneity among severe community-acquired pneumonia patients stratified by respiratory virus status: a secondary analysis of combined retrospective and prospective multicenter cohorts.
    Int J Infect Dis. 2026 Nov 19:109257. doi: 10.1016/j.ijid.2026.109257.
    PubMed         Abstract available

  5. XIANG C, Yan M, Cao B, Wang Y, et al
    Natural Killer Cell Decrease at Admission Is Associated With Severe Outcomes in Hospitalized Influenza and COVID-19: An 8-Year Retrospective Cohort Study.
    Int J Infect Dis. 2026 Nov 18:109250. doi: 10.1016/j.ijid.2026.109250.
    PubMed         Abstract available

  6. ISHIOKA H, Uchino S, Shiotsuka J
    Temporal Changes in Body Mass Index among Patients with Severe COVID-19 in Japan.
    Int J Infect Dis. 2026 Nov 14:109255. doi: 10.1016/j.ijid.2026.109255.
    PubMed         Abstract available

  7. MUKHERJEE A, Anand T, Singh KJ, Sharma L, et al
    Reinfection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) among healthcare workers in India.
    Int J Infect Dis. 2026 Nov 13:109249. doi: 10.1016/j.ijid.2026.109249.
    PubMed         Abstract available


    J Travel Med

  8. MEMISH ZA, Sreffen R
    Respiratory Infections at Mass Gatherings: A Travel-Medicine Review with Hajj and Umrah as a Longitudinal Case Study.
    J Travel Med. 2026 Nov 14:taag105. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  9. YANG L, Luo M, Lu Y, Wang H, et al
    Establishment and characterization of a recombinant VSV-based pseudotyping platform for studying RSV F-mediated entry and antibody-mediated neutralization.
    J Virol. 2026 Nov 18:e0146626. doi: 10.1128/jvi.01466.
    PubMed         Abstract available

  10. HARMAN MAJ, Gaynor KU, Papa G, Pellegrino S, et al
    Investigation of anti-SARS-CoV-2 multimeric bicyclic peptide inhibitors in a range of preclinical therapeutic settings.
    J Virol. 2026 Nov 18:e0122426. doi: 10.1128/jvi.01224.
    PubMed         Abstract available

  11. GOHMANN L, Reid W, Tsai B
    Primer: Virus entry and uncoating.
    J Virol. 2026 Nov 18:e0165626. doi: 10.1128/jvi.01656.
    PubMed         Abstract available


    JAMA

  12. RUBIN R
    After COVID-19 Vaccination, Why Do Some People Run a Fever?
    JAMA. 2026 Nov 13. doi: 10.1001/jama.2026.22638.
    PubMed        


    Lancet Infect Dis

  13. KIMURA Y, Tanimura K, Inoue N, Herbrecht R, et al
    Mortality and prognostic factors in invasive aspergillosis: a systematic review and individual patient data meta-analysis.
    Lancet Infect Dis. 2026 Nov 19:S1473-3099(26)00525.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  14. WINN AK, Anglin O, Anderson EL, Prill MM, et al
    Respiratory Virus Activity - United States, July 2025-June 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:662-668.
    PubMed         Abstract available


    Nature

  15. GRIPPIN AJ, Marconi C, Copling S, Li N, et al
    Author Correction: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade.
    Nature. 2026 Nov 20. doi: 10.1038/s41586-026-10974.
    PubMed        

  16. LEDFORD H
    University students are biggest spreaders of COVID.
    Nature. 2026 Nov 19. doi: 10.1038/d41586-026-03746.
    PubMed        

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, Nov. 21 '26)

 


    Ann Intern Med

  1. REIS G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, et al
    Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial.
    Ann Intern Med. 2026 Oct 6. doi: 10.7326/ANNALS-26-02144.
    PubMed         Abstract available


    Epidemiol Infect

  2. CHEN Y, Li J, Luo F, Ling F, et al
    Epidemiology of influenza before, during, and after the COVID-19 pandemic in China: An observational study from Zhejiang, China (2010-2023).
    Epidemiol Infect. 2026 Nov 20:1-14. doi: 10.1017/S0950268826102465.
    PubMed        


    J Infect Dis

  3. YANG Y, Smith M, Ho F, Truscon R, et al
    A prospective, comparative cohort analysis of influenza antibody waning in Michigan and Hong Kong during periods of low influenza circulation.
    J Infect Dis. 2026 Nov 17:jiag559. doi: 10.1093.
    PubMed         Abstract available

  4. HOSSAIN MP, Chen D, Yeung A, Adam DC, et al
    Inferring Diagnostic Serial Intervals to Understand COVID-19 Transmission Dynamics in Hong Kong and Mainland China.
    J Infect Dis. 2026;234:e1236-e1246.
    PubMed         Abstract available

  5. RATU A, Rabukawaqa I, McGregor R, Sassen J, et al
    Neutralisation capacity against SARS-CoV-2 ancestral, Delta and Omicron variants before and after heterologous booster vaccination in Fijian health system workers.
    J Infect Dis. 2026 Jul 17:jiag363. doi: 10.1093.
    PubMed         Abstract available

  6. BORRIELLO F, Koh GCKW, Troconiz IF, Nassirpour R, et al
    Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix.
    J Infect Dis. 2026;234:747-757.
    PubMed         Abstract available


    J Virol

  7. WANG M, Zhao C, Peng R, Bai S, et al
    Structural basis of avian-to-human receptor-binding adaptation in H9Ny influenza A virus hemagglutinin.
    J Virol. 2026 Nov 18:e0151126. doi: 10.1128/jvi.01511.
    PubMed         Abstract available

  8. BARKHYMER AJ, Becker JT, Shepherd FK, Mickelson CK, et al
    A chicken interferon-stimulated gene screen reveals limited genes restricting influenza virus replication.
    J Virol. 2026 Nov 17:e0124326. doi: 10.1128/jvi.01243.
    PubMed         Abstract available

  9. COLARUSSO A, Stephenson KE, Collier A-RY, Wegmann F, et al
    Early innate immune signatures correlate with Ad26.COV2.S vaccine immunogenicity and protective efficacy.
    J Virol. 2026 Oct 26:e0149426. doi: 10.1128/jvi.01494.
    PubMed         Abstract available

  10. ULUSAN S, Markmann AJ, Vanna UP, Castillo I, et al
    Pooled intravenous immunoglobulins exhibit broad binding and Fc-mediated activity against diverse SARS-CoV-2 variants.
    J Virol. 2026 Oct 22:e0147126. doi: 10.1128/jvi.01471.
    PubMed         Abstract available

  11. KEITH AD, Keen MM, Frank F, Lam WA, et al
    Variant escape site mapping and characterization of SARS-CoV-2 nucleocapsid rapid antigen test antibodies.
    J Virol. 2026 Oct 14:e0100126. doi: 10.1128/jvi.01001.
    PubMed         Abstract available

  12. DIONNE K, Belanger E, Benlarbi M, Beaudoin-Bussieres G, et al
    Pre-existing cross-subtype serological responses against H5Nx in health care workers.
    J Virol. 2026;100:e0131026.
    PubMed         Abstract available

  13. LIU Z, Zhang J, Ding Q, Yang C, et al
    Real-time tracking of dual-labeled fluorescent SARS-CoV-2 reveals that the nucleocapsid mutations R203K/G204R accelerate viral uncoating.
    J Virol. 2026 Oct 6:e0108626. doi: 10.1128/jvi.01086.
    PubMed         Abstract available

  14. SILVA MARINHO PE, Ghimire D, Tsai Silva J, Devlin J, et al
    Subtype-specific differences in susceptibility to monoclonal antibodies and vaccines among contemporary RSV-A and RSV-B isolates.
    J Virol. 2026 Oct 5:e0122126. doi: 10.1128/jvi.01221.
    PubMed         Abstract available

  15. LI A, Si H, Wu K, Zhang Q, et al
    Natural variation in BtSARSr-CoV nsp12 harbors adaptive mutations that enhance viral replication and spillover risk in humans.
    J Virol. 2026 Oct 5:e0134326. doi: 10.1128/jvi.01343.
    PubMed         Abstract available


    J Virol Methods

  16. ZHAO M, Qiu P, Wang W, Li Y, et al
    A one-step multiplex real-time reverse transcription quantitative PCR assay for rapid and simultaneous detection of human parainfluenza virus, human metapneumovirus, and rhinovirus in patients with acute respiratory tract infection.
    J Virol Methods. 2026;348:115504.
    PubMed         Abstract available

  17. CAO D, Li J, Zu Y, Wang X, et al
    Development of a quantum dot-based immunochromatographic strip for the rapid detection of H9N2 subtype avian influenza virus.
    J Virol Methods. 2026;348:115503.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  18. WINN AK, Anglin O, Anderson EL, Prill MM, et al
    Respiratory Virus Activity - United States, July 2025-June 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:662-668.
    PubMed         Abstract available


    PLoS Comput Biol

  19. GOLDBERG EE, Kupperman MD, Ke R
    Estimating rates of SARS-CoV-2 lineage spread using graph spectra from genetic sequence data.
    PLoS Comput Biol. 2026;22:e1014920.
    PubMed         Abstract available


    PLoS One

  20. SANDES-FREITAS TV, Requiao-Moura L, Garcia VD, Manfro RC, et al
    Allograft function in kidney transplant recipients following COVID-19.
    PLoS One. 2026;21:e0356034.
    PubMed         Abstract available

  21. SATO S, Matsumoto M, Wakabayashi C, Oki I, et al
    Spatiotemporal analysis of COVID-19 in Japan: The twelve epidemic waves from 2020 to 2025.
    PLoS One. 2026;21:e0363045.
    PubMed         Abstract available

  22. MIGEON A, Laurent E, Chautard R, Desmars H, et al
    Bevacizumab and thrombosis risk in cancer patients with COVID-19: A national retrospective cohort study (TIC-TAC).
    PLoS One. 2026;21:e0362952.
    PubMed         Abstract available

  23. NIESSEN FA, Veldhuijzen IK, Boere TM, Hooiveld M, et al
    Developing a syndromic case definition for timely surveillance of severe acute respiratory infections (SARI) based on financial claim codes in the Netherlands.
    PLoS One. 2026;21:e0338157.
    PubMed         Abstract available

  24. THIT WM, Paek SC, Felix MS, Lamy FR, et al
    Misinformation-based preventive behaviors during the COVID-19 pandemic in Myanmar: A cross-sectional study.
    PLoS One. 2026;21:e0362976.
    PubMed         Abstract available

  25. CUGMAS M, Ferligoj A, Kogovsek T, Batagelj Z, et al
    Social support networks of older adults before, during and after the COVID-19 pandemic.
    PLoS One. 2026;21:e0363274.
    PubMed         Abstract available

  26. CHEN S, Cai M, Song Y, Xu Z, et al
    The global burden of Alzheimer's disease and related dementias: New public health intervention targets driven by the long-term impact of COVID-19 and sex and age differences.
    PLoS One. 2026;21:e0359947.
    PubMed         Abstract available

  27. ASAMNEW A, Shure W, Asres MS, Wondimeneh Y, et al
    Prevalence and associated factors of influenza A virus infection among patients with acute respiratory tract infections in Gondar City, Northwest Ethiopia.
    PLoS One. 2026;21:e0357953.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  28. RICHARDSON BD, Aiello AE, Hudgens MG
    Physical distancing to prevent influenza-like illness on a college campus: The eX-FLU trial.
    Proc Natl Acad Sci U S A. 2026;123:e2626810123.
    PubMed         Abstract available

  29. KIM D, Pasco R, Johnson KE, Fox SJ, et al
    Local influenza forecasts outperform state-level forecasts in the United States.
    Proc Natl Acad Sci U S A. 2026;123:e2616357123.
    PubMed         Abstract available


    Vaccine

  30. CAO Y, Kwan MYW, Murphy C, Chan ELY, et al
    Epidemiology of influenza C in Hong Kong inferred from pediatric hospitalization data.
    Vaccine. 2026;96:129278.
    PubMed         Abstract available


    Virology

  31. WU Y, Yu M, Feng L, Peng Q, et al
    Targeting TMPRSS2 protects against influenza-associated lung injury by suppressing PAR-2/MMP-9 axis.
    Virology. 2026;626:111142.
    PubMed         Abstract available


    Virus Res

  32. OUYANG F, Chen X, Wang M, Huang X, et al
    Serum untargeted metabolomics reveals infection-associated metabolic alterations in chikungunya, dengue, and influenza A virus infections.
    Virus Res. 2026 Nov 17:199832. doi: 10.1016/j.virusres.2026.199832.
    PubMed         Abstract available

  33. UEMURA K, Toba S, Kusakabe S, Sasaki M, et al
    In vivo antiviral efficacy and safety of 5-hydroxymethyltubercidin against DENV2 and SARS-CoV-2.
    Virus Res. 2026;373:199817.
    PubMed         Abstract available

#Bundibugyo virus disease #outbreak in the #DRC and #Uganda at day 100: an #ESCMID Emerging Infections Subcommittee update

 


Abstract

Background

The 2026 Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo (DRC) and Uganda has challenged epidemic control despite rapid expansion of response capacity.

Objectives

To reassess the threats identified by the ESCMID Emerging Infections Subcommittee at day 100 and identify clinical and public-health priorities.

Sources

This narrative update draws on published literature and WHO, Africa CDC, ECDC, and national public health reports, using 22 August 2026 as the day-100 analytical cut-off, with data through 20 October for a subsequent update.

Content

By 22 August, the DRC had reported 5514 confirmed cases and 2642 deaths in 57 health zones across six provinces, making it the largest recorded outbreak in the DRC and the second-largest Ebola outbreak by confirmed case count. Uganda contained 20 cases, and its outbreak was declared over on 27 August. By 20 October, the DRC had reported 9704 cases and 4687 deaths in 66 health zones across eight provinces; Kenya had reported nine epidemiologically linked cases and Nigeria one. Contact follow-up improved, but many transmission chains remained unidentified. BDBV-specific diagnostics, therapeutic and post-exposure prophylaxis trials, and vaccine studies expanded, yet no vaccine or virus-specific treatment had demonstrated clinical efficacy. Cross-reactive antibody responses after licensed Ebola vaccination do not establish protection against BDBV. ECDC assessed infection likelihood for EU/EEA residents as very low.

Implications

Epidemic control requires complete contact tracing complemented by active case-finding, earlier referral, high-quality supportive care, health-worker protection, community engagement, flexible financing and preservation of essential health services.


Source: Clinical Microbiology and Infection Journal, https://doi.org/10.1016/j.cmi.2026.10.042

____

#Kazakhstan, #Hospital #queues and high temperatures in #children: What's happening with ARVI in #Almaty? (Kazinform, Nov. 21 '26)

 


Almaty residents are reporting a large number of sick children and long lines at hospital emergency rooms. Doctors attribute the increase to the seasonal increase in acute respiratory viral infections and influenza, reports a Kazinform correspondent.



    One city resident shared a story on the social network Threads about the situation in medical facilities and complained about her child's high fever, which was difficult to bring down.

        "The hospitals are overcrowded! There's a line of 50 people in the emergency room. There are a lot of sick people, especially children. Many have the same symptoms: a high fever of 39-40 degrees Celsius, which is difficult to bring down and then rises again. Our child is also sick. The temperature is 39-40 degrees Celsius, very difficult to bring down, and if it does drop, it doesn't last long. We don't know what to do anymore. What's going on?" wrote an Almaty resident. 

    In the comments, other residents also reported cases of illness among children. Many report similar symptoms—high fever that persists for several days.

        "My child's temperature is 102.4 degrees Fahrenheit and it won't go down. Today I refused hospitalization at the infectious diseases hospital. They said there was a waiting list and too many children," one user shared.

    Some users attribute the increase in the number of cases to the seasonal spread of influenza and acute respiratory viral infections.


Additional beds will be deployed at the hospital

    The Children's City Clinical Infectious Diseases Hospital of Almaty commented on the situation. The medical facility reported a seasonal increase in acute respiratory viral infections and influenza cases and measures to increase its hospital bed capacity.

        "Due to the seasonal increase in acute respiratory viral infections and influenza, the number of hospital beds for children in Almaty is increasing. Medical organizations are taking the necessary measures to ensure access to medical care. There is no reason to panic," the response stated.

    Specifically, the Children's City Clinical Infectious Diseases Hospital plans to deploy 67 additional reserve beds. This will increase the facility's bed capacity from 360 to 427.


25 cases of influenza have been detected in Almaty.

    The Department of Sanitary and Epidemiological Control added that the epidemiological situation in the city remains stable. Despite the annual seasonal increase in acute respiratory viral infections, no exceedance of the control level has been recorded.

        "Since the beginning of the epidemic season, 25 confirmed cases of influenza have been registered. Laboratory monitoring indicates that two types of influenza viruses—A/H1N1 and B—are circulating in the city. Other pathogens causing acute respiratory viral infections are also being identified, including rhinovirus, parainfluenza virus, respiratory syncytial virus, bocavirus, and seasonal coronavirus. No new, unknown viruses have been identified," the department noted.

    The department emphasized that healthcare facilities had prepared in advance for the seasonal increase in cases. Outpatient clinics have established mobile teams to handle house calls, and special filters have been set up to admit patients with symptoms of acute respiratory viral infections and influenza. Infectious disease hospitals have allocated additional beds for the hospitalization of sick patients.

    In addition, flu vaccinations continue in the city. As of November 19, 2026, 251,102 people have been vaccinated, including 248,780 from risk groups.


What do experts recommend?

    The State Sanitary and Epidemiological Survey (DSEC) reminded residents of the need to observe preventative measures during the seasonal increase in cases. Experts recommend regularly washing hands, covering your mouth and nose when coughing and sneezing, wearing masks if you have symptoms, and limiting attendance at public events whenever possible.

    Parents are advised not to send sick children to schools and daycares, and to seek medical attention promptly at the first signs of infection. The department also urged residents not to self-medicate and to take medications only as prescribed by a doctor.

    We previously discussed how to protect yourself from the flu and acute respiratory viral infections during the fall and winter, why it's important to get vaccinated promptly, and what common mistakes to avoid during treatment.


Source: Kazinform, https://www.inform.kz/ru/ocheredi-v-bolnitsah-i-visokaya-temperatura-u-detey-chto-proishodit-s-orvi-v-alm-b0c6edb0

____

#Ebola disease caused by #Bundibugyo virus - #DRC, #Kenya and #Nigeria (WHO D.O.N., Nov. 21 '26)

 


{Excerpts}

Situation at a glance

    Since the publication of the previous Disease Outbreak News on 6 November 2026, additional confirmed cases and deaths have been reported in the Democratic Republic of the Congo. 

    While some areas have seen a slight decline in cases, sustained, high-level transmission continues overall in the country. 

    As of 17 November 2026, a total of 11 613 confirmed cases, including 5678 deaths (crude case fatality ratio: 48.9%), have been reported across 68 health zones in eight provinces, with active transmission ongoing in 48 health zones. 

    Ituri and Nord Kivu remain the most affected provinces, while Sud-Kivu and Sud Ubangi have not reported cases for more than 42 days. 

    The high proportion of deaths occurring in communities, meaning outside of dedicated treatment centres, especially among young children, continues to highlight challenges in early case detection and timely access to appropriate care. 

    Of the 720 deaths reported since 28 October (last three weeks), 452 occurred in communities and 268 in treatment centres. 

    Since the last Disease Outbreak News, no new cases have been reported from Kenya or Nigeria; and no new country has reported confirmed cases. 

    Both countries have started a 42-day countdown to declare the end of their outbreaks. 

    However, the high-level transmission in the Democratic Republic of the Congo calls for continued need for readiness in the region, including cross-border surveillance, points of entry monitoring, timely case detection and coordinated preparedness and response measures. 

    Six months into the outbreak of Bundibugyo virus disease (BVD) in the Democratic Republic of the Congo, the response has expanded significantly, but further scale up is needed, with rising insecurity remaining the greatest obstacle to the expansion of operations. 

    The next phase must prioritize quality, reach and community trust, alongside sustained funding, coordination and security to save lives and end the outbreak. 

On 18 November 2026, the Director-General of WHO, concurring with the advice of the IHR Emergency Committee formulated at its third meeting, on 17 November 2026, determined that the event continues to constitute a public health emergency of international concern (PHEIC). 

    Updated recommendations to the government of the Democratic Republic of the Congo and all other States Parties will be issued in the coming days.


Description of the situation

    Cases have been reported in five countries since the declaration of the outbreak on 15 May 2026: the Democratic Republic of the Congo, France, Kenya, Nigeria, and Uganda. 

    The outbreaks in France and Uganda have been controlled since August, while Kenya and Nigeria continue with heightened surveillance as they count down to 42 days, completing two maximum incubation periods since the last confirmed cases were either discharged or medically evacuated from the country.

    On 26 October 2026, Switzerland reported the medical evacuation of the case, who received medical care in Geneva, Switzerland. 

    The patient recovered and was discharged on 11 November testing PCR-negative for Bundibugyo virus for a second time.

    On 18 November 2026, the United Kingdom of Great Britain and Northern Ireland reported that a medically evacuated health and care worker from the Democratic Republic of the Congo had recovered and been discharged from hospital.


Democratic Republic of the Congo

    An additional 945 confirmed cases, including 480 confirmed deaths, have been reported in the Democratic Republic of the Congo since the previous Disease Outbreak News was published.

    In the last 21-day period, as of 17 November, 1417 new confirmed cases were reported, with Ituri accounting for 668 (13% decrease) cases, Nord Kivu for 635 (8% increase) cases, Haut-UĂ©lĂ© for 90 (13% increase) cases, Tshopo for 20 (47% decrease) cases and Nord-Ubangi for four cases. No new cases were reported in Bas-UĂ©lĂ©, Sud Kivu or Sud-Ubangi during that period.

    As of 17 November, cumulative confirmed cases have reached 11 613, including 5678 deaths and 3148 recoveries. The overall crude CFR is 48.9%.

    Confirmed cases have now been identified in 68 health zones across eight provinces. Forty-eight of the 68 affected health zones reported at least one new case during the preceding 21 days, while 20 reported no recent cases. 

    Beni, Bunia, and Mandima have reported the highest number of cases and deaths in the preceding 21 days. Ituri remains the most extensively affected province, with 28 of 36 health zones reporting cases during this outbreak, followed by Nord Kivu (17/34), Haut-UĂ©lĂ© (8/13), Tshopo (7/23), Bas-UĂ©lĂ© (4/11), Nord-Ubangi (2/11), Sud Kivu (1/34) and Sud-Ubangi (1/16). Watsa in Haut-UĂ©lĂ© province is the most recently affected health zone, reporting 11 confirmed cases.

    Six months into the BVD outbreak, the response has expanded significantly, but transmission remains persistent and geographically widespread. WHO, the national Government and partners have strengthened surveillance, treatment, laboratory capacity and community engagement, yet high community mortality, insecurity, displacement and a fragile health system continue to undermine progress.

    The next phase will need to focus on scaling up, but also on improving the reach, quality and impact of the response. Early detection, quality care, contact tracing, infection prevention and community trust remain critical. Sustained funding, strong coordination and safe access to communities will be essential.

    The third International Health Regulations (IHR) Emergency Committee meeting regarding the epidemic of BVD in the Democratic Republic of the Congo took place on 17 November. Following the advice of the Committee, the Director-General agreed that the ongoing outbreak remains a PHEIC. Updated recommendations to the government of the DRC and all other States Parties will be issued in the coming days and reported in the next Disease Outbreak News publication.  

(...)

    While Nord Kivu reported the highest number of cases in the last seven days (235 cases (40% increase compared to the previous seven days) as of 17 November), Ituri remains the most affected province since the outbreak was declared, with 7946 cumulative confirmed cases and 3751 deaths, with CFR of 47%. Nord Kivu follows with 2996 confirmed cases and 1654 deaths, and continues to record the highest provincial CFR, at 55%. 

    Haut-UĂ©lĂ© has reported 534 cases and 231 deaths, while Tshopo has recorded 109 cases and 35 deaths. The less-affected provinces continue to report substantially fewer cases, but transmission persists in several of them. The continued occurrence of cases across multiple provinces shows that the outbreak remains geographically active even as intensity varies between health zones. Sud-Kivu and Sud Ubangi have not reported cases for more than 42 days.

    As of 17 November 2026, the average proportion of contacts seen daily over the previous 14-day period is 81%, remaining below the required threshold of 95% for a daily average of the proportion of contacts seen over the previous 14-day period. Two provinces were at or above the 95% threshold: Bas-Uele (100%, 56/56) and Nord-Ubangi (99%, 140/138) Five provinces were below the threshold: Haut-UĂ©lĂ© (86%; 1741/1495), Ituri (86% (9564/11 104), Nord-Kivu (77%; 16 015/12 313), Tshopo (68%; 720/526), and Sud-Ubangi (63%; 127/80). Strengthened contact follow-up is required, particularly in provinces below the target, to achieve the minimum threshold of 95%.

(...)


Kenya

    As of 17 November 2026, the cumulative confirmed cases reported in Kenya are nine, including two deaths, with a crude CFR of 22.2%. All eight secondary cases were epidemiologically linked to the imported index case and associated with one cluster (four family members of the index case and four health and care workers).  All seven hospitalized cases have recovered and been discharged (the last case was discharged on 11 November). A 42-day countdown is underway and includes heightened surveillance.

    There is currently no evidence of transmission outside this cluster, and there have been no new confirmed cases since 19 October 2026.  Additionally, all eight secondary cases were already under quarantine as known contacts when they developed symptoms.  

    As of 17 November, of the 135 cumulative contacts identified since the first confirmed case, eight subsequently became confirmed cases and nine contacts left Kenya (relevant National IHR Focal Points were notified). All have completed the 21-day follow-up on 11 November 2026.

(...)


Nigeria

    On 20 October 2026, Nigeria reported one laboratory-confirmed imported case of BVD in the Federal Capital Territory Abuja. On 26 October 2026, Switzerland reported the medical evacuation of the case, who received medical care in Geneva, Switzerland. The patient recovered and was discharged on 11 November, following two PCR-negative test results for Bundibugyo virus.

    As of 13 November, a cumulative of 62 contacts had been identified in Nigeria for follow-up and all the contacts have completed the 21-day follow-up period. National authorities, with support from WHO and partners, have intensified contact tracing, case investigation and infection prevention and control measures, including the provision of essential supplies and personal protective equipment for health workers. Investigations are ongoing to establish the likely source of infection and reconstruct the travel and exposure history of the imported case. WHO has urged countries across the region to strengthen surveillance, laboratory diagnostic capacity, rapid response readiness and cross-border preparedness to mitigate the risk of further transmission.

(...)

Citable reference: World Health Organization (20 November 2026). Disease Outbreak News; Bundibugyo Virus Disease in the Democratic Republic of the Congo, Kenya and Nigeria. Available at:  https://www/who.int/emergencies/disease-outbreak.news.item/2026-DON630 


Source: World Health Organization, https://www/who.int/emergencies/disease-outbreak.news.item/2026-DON630

____

History of Mass Transportation: The BREL Class 87 022 Electric Locomotive working in Bulgaria

 


{Click on Image to Enlarge}

___

By Spookywestie - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/wiki/Special:Redirect/page/83872207


Source: Wikipedia, https://en.wikipedia.org/wiki/British_Rail_Class_87

____

Friday, November 20, 2026

#Portugal - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) ( #poultry ) - Immediate notification

 


{Extract}

(...)

A Poultry Farm in the SantarĂ©m Region.

(...)


Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8014

____

#UK - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) ( #poultry ) - Immediate notification

 


{Extract}

(...)

{Northern Ireland}

    Over 23k, 40 week-old layer hens. Positive test for HPAI H5N1, clinical signs presented prior to testing.

(...)


Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8010

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, Nov. 20 '26)

 


{Extract}

(...)

A(H5) detections in the past week

Time Period: November 08, 2026 - November 14, 2026

    -- A(H5) Detection: 15 site(s) (3.2%)

    -- No Detection: 456 site(s) (96.8%)

    -- No samples: 146 site(s)


{Click on Image to Enlarge}

___

(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

#USA, #H5 Avian #Influenza: Current #Situation (CDC, Nov. 20 '26): One New Human Case in #Oregon

 


{Extract}

(...)

National situation summary since 2024

    ° Person-to-person spread: None

        § There is no known person-to-person spread at this time.

    ° Current public health risk: Low

        § The current public health risk is Low.

    ° Cases in the U.S.: 75 cases {+1 in Oregon}

    ° Deaths in U.S.: 3 deaths {0}

(...)


Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/situation-summary/?CDC_AAref_Val=https://www.cdc.gov/flu/avianflu/avian-flu-summary.htm

____

#USA, One New Confirmed #Human Case of Infection with #H5N1 Avian #Influenza Virus in #Oregon (CDC, Nov. 20 '26)

 


{Extract}

(...)

Novel Influenza A Virus Infections

    ° One confirmed human infection with influenza A(H5) virus was reported to CDC this week. 

        § To date, human-to-human transmission of influenza A(H5) virus has not been identified in the United States.

    ° The case was reported by the Oregon Health Authority and occurred in a worker aged ≥18 years at a commercial dairy cattle farm where highly pathogenic avian influenza (HPAI) A(H5) virus has been detected in cows. 

        § This individual developed eye irritation during the week ending November 15, 2026 (Week 45), which they reported to the local health department. 

        § Specimens were collected from the individual and tested at the state public health laboratory where a conjunctival specimen tested presumptive positive for influenza A(H5) virus using the CDC influenza A(H5) assay. 

        § Influenza A(H5) virus was confirmed at CDC. This is the first influenza A(H5) case associated with a dairy worker in Oregon.

    ° There has been a total of four influenza A(H5) cases in dairy workers reported in 2026.

    ° Notification to WHO of this case was completed per International Health Regulations (IHR). More information regarding IHR can be found at http://www.who.int/topics/international_health_regulations/en/.

    ° The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/position_statements_files_2023/24-ID-09_Novel_Influenza_A.pdf.

    ° An up-to-date human case summary during the 2024 outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

    ° Information about avian influenza is available at https://www.cdc.gov/bird-flu/.

    ° Interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevention/hpai-interim-recommendations.html.

    ° The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

(...)


Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/fluview/surveillance/2026-week-45.html

____

#USA, Weekly #US #Influenza #Surveillance Report: Key Updates for Week 45, ending November 14, 2026 (CDC, summary)

 


{Summary}

(...)

Key Points

    ° Multiple seasonal influenza surveillance indicators continue to increase nationally.

    ° Many surveillance indicators are higher than typically observed at this time of year, but an earlier increase in activity does not necessarily lead to a higher seasonal peak or greater severity overall.

    ° During Week 45 (the week ending November 14, 2026), of the 613 influenza viruses reported by public health laboratories, 608 were influenza A and 5 were influenza B. Of the 365 influenza A viruses subtyped, 352 (96.4%) were influenza A(H1N1)pdm09, 12 (3.3%) were A(H3N2), and 1 (0.3%) was A(H5).

    ° Since Week 21 (the week ending May 30, 2026), 84.8% of the influenza A viruses reported have been A(H1N1)pdm09 and among these, the majority have been HA subclade E (newly designated alias of D.3.1.1).

    ° The influenza A(H1N1) viruses detected this season are still A(H1N1)pdm09 viruses, which emerged in 2009 and have circulated globally since. Influenza viruses are constantly changing, often requiring updates to influenza vaccines every season.

    ° Historically, influenza A(H1N1)pdm09 viruses have changed less often than A(H3N2) viruses. This week, recently  circulating influenza A(H1N1)pdm09 viruses which were previously designated D.3.1.1 HA subclade  have been reclassified into subclade E (with newly designated HA subclades E.1 to E.4), each with different combinations of genetic changes in their HA genes.

    ° It is too early to know what viruses may predominate or to say whether there might be implications on flu vaccine effectiveness this season. So far, almost all the influenza viruses collected and antigenically characterized in the U.S. since Week 21 are antigenically similar to their respective influenza vaccine reference viruses based on CDC laboratory assays.

    ° Two pediatric deaths associated with season influenza virus infection occurring during the 2026-2027 influenza season were reported to CDC this week for a total of seven deaths this season.

    ° Because case investigation takes time, flu-associated deaths in children may be reported to CDC weeks after they occur; counts are preliminary and may increase. All reported cases meet the influenza-associated pediatric mortality case definition.

    ° The preliminary in-season severity assessment has classified the severity of influenza activity at this point in the season as low across all ages and all age groups. The severity assessment for the season changes with flu activity.

    ° CDC estimates that there have been at least 3,700,000 illnesses, 50,000 hospitalizations, and 2,800 deaths associated with flu so far this season.

    ° CDC’s FluSight forecasts predict a likely increase nationally in both flu hospital admissions and the percentage of emergency department visits due to flu for the week ending November 28. The number of new flu hospital admissions is forecast to range from 9,200 to 36,100 admissions, while the national percentage of emergency department visits due to flu is forecast to range from 1.7% to 7.6%.

    ° Annual seasonal flu vaccination is recommended. Influenza vaccines are available for persons aged 6 months and older. People who are recommended for influenza vaccination but have not been vaccinated yet this season are encouraged to be vaccinated now. Influenza vaccination coverage estimates and influenza vaccine doses distributed for this season are available in FluVaxView.

    ° There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for patients at higher risk for influenza complications.1

    ° One confirmed human case of avian influenza A(H5) virus infection was reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

    ° Influenza viruses are among several viruses contributing to respiratory disease activity. CDC is providing updated, integrated information about COVID-19, flu, and respiratory syncytial virus (RSV) activity on a weekly basis.

(...)


Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/fluview/surveillance/2026-week-45.html

____

#Poland - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


{Extract}

(...)

Three Wild Mute Swans in the Zachodniopomorskie Region.

(...)


Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8009

____

#Korea (Rep. of) - #Influenza A #H5 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


{Exract}

(...)

A wild bird of unspecified species in the Jeollanam-do Region.

(...)


Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8006

____

#Australia, #H5 avian #influenza events in #wildlife (Dept. of Agriculture, Nov. 20 '26)



{Extract}

(...)

Event data

    As of 4pm AEST, 19 November 2026, Australia has 745 confirmed events of H5 bird flu in wildlife.

        § 10 in Western Australia (WA)

        § 344 in South Australia (SA)

        § 86 in New South Wales (NSW)

        § 2 in Queensland (QLD)

        § 249 in Victoria (VIC)

        § 53 in Tasmania (TAS)^

        § 1 in Other Territories#

    {^} Includes events on Macquarie Island

    {#} Jervis Bay Territory (Commonwealth jurisdiction)

(...)


Source: Australian Department of Agriculture, https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu

____

Thursday, November 19, 2026

#USA, #Oregon Health Agency confirms state’s first #human case of avian #influenza #H5 virus of 2026 (Nov. 19 '26)

 


November 19, 2026


H5 bird flu found in individual linked to Morrow County dairy farm


PORTLAND, Ore. – Oregon Health Authority has confirmed the state’s first human case of highly pathogenic avian influenza (HPAI) of 2026. 

    The individual’s infection is linked to an outbreak among cattle at a Morrow County dairy farm.

    Epidemiologists at OHA’s Public Health Division received confirmation of the human HPAI case from the Oregon State Public Health Laboratory on Nov. 18. 

    They have been working closely with the Oregon Department of Agriculture (ODA) and Morrow County Public Health on the outbreak. 

    ODA provides PPE and training in its use to affected farm workers during an outbreak, while public health monitors exposed individuals.

    After developing mild symptoms of HPAI, the affected individual was promptly treated with the antiviral medicine oseltamivir and tested. 

    They did not require hospitalization. 

    Morrow County public health officials have also offered oseltamivir to members of the individual’s household out of an abundance of caution.

    The virus is not known to spread human-to-human. 

    Risk to the public is extremely low.

        “This is not cause for alarm. Rather, it is evidence that the surveillance and response system we have in place is working,” said Melissa Sutton, M.D., medical director for respiratory viral pathogens at OHA. 

        “Our goal is to ensure that all symptomatic farm workers receive prompt testing and treatment to prevent severe disease. We appreciate the partnership with individuals on the farm during this challenging time.”

    While the seasonal flu vaccine does not protect against HPAI, getting the seasonal flu vaccine can help reduce the risk of getting sick with human influenza viruses, which can, in turn, reduce the risk of co-infection with both a human seasonal virus and an avian virus, according to the Centers for Disease Control and Prevention (CDC).

    In Oregon, public health has monitored more than 300 people exposed to sick animals since 2022; one human case of bird flu was identified in 2024 associated with a commercial poultry outbreak.


###


Source: US State of Oregon Department of Health, https://www.oregon.gov/oha/ERD/Pages/OHA-confirms-states-first-human-case-of-avian-influenza-of-2026-11.19.2026.aspx

____

Respiratory #Virus #Activity — #USA, July 2025–June 2026

 


Abstract

Respiratory viral illnesses are common and can lead to severe outcomes, including hospitalization and death. U.S. trends in respiratory virus activity during July 2025–June 2026 were analyzed using data from six complementary public health surveillance systems. Respiratory syncytial virus (RSV) activity occurred unusually late in most U.S. regions. SARS-CoV-2 circulated nationally with typical bimodal peaks that occurred in August 2025 and January 2026. Annual RSV-associated hospitalization rates (number of hospitalizations per 100,000 persons) were highest among infants aged <12 months (790.2; 95% CI = 757.9–825.3), followed by children aged 12–23 months (611.9; 95% CI = 586.3–639.8) and adults aged ≥75 years (352.1; 95% CI = 309.9–407.7). Annual RSV rates overall and by age group did not exceed those observed during 2022–2025. COVID-19–associated hospitalization rates were highest among adults aged ≥75 years (361.2), infants aged <6 months (173.3), and adults aged 65–74 years (111.4). Newly established 2025–2026 national pediatric mortality surveillance provisionally identified 34 RSV-associated pediatric deaths from 35 reporting jurisdictions and 31 COVID-19–associated pediatric deaths from 43 reporting jurisdictions. RSV sequencing did not identify variant substitutions associated with reduced susceptibility to the available RSV monoclonal antibodies for infants. Most SARS-CoV-2 lineages were JN.1 descendants, but detections of BA.3.2, a highly divergent SARS-CoV-2 variant, increased. Circulation of other respiratory viruses followed usual historical patterns. Staying current with recommended RSV and COVID-19 vaccinations reduces the risk for severe illness and disease caused by these viruses.


Source: Morbidity and Mortality Weekly Report Journal, http://dx.doi.org/10.15585/mmwr.mm7545a2

____

Autochthonous #dengue #outbreak spreading from a holiday site to #visitors’ places of residence, #Tuscany, #Italy, August to October 2026

 


Abstract

Between August and October 2026, 49 autochthonous dengue cases were notified in Italy. Of these, 42 were exposed at a Tuscan coastal holiday site, and diagnosed after returning home, in 14 municipalities across seven provinces. Seven additional cases were identified, six in two areas where viraemic cases returned home and one near the holiday site. Dengue virus serotype 2, lineage 2II_F.1.1.5, was identified. When exposure occurs at holiday destinations, investigation and vector control should extend to places where cases reside.


© Creative Commons License. This work is licensed under a Creative Commons Attribution 4.0 International License.


Source: Eurosurveillance Journal, https://doi.org/10.2807/1560-7917.ES.2026.31.46.2600909

____

My New Space

Most Popular Posts